Logo image of CNTA

CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Fundamental Analysis

NASDAQ:CNTA - US1523091007 - ADR

17 USD
-0.01 (-0.06%)
Last: 8/25/2025, 8:12:08 PM
17 USD
0 (0%)
After Hours: 8/25/2025, 8:12:08 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CNTA. CNTA was compared to 547 industry peers in the Biotechnology industry. CNTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNTA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTA had negative earnings in the past year.
CNTA had a negative operating cash flow in the past year.
In the past 5 years CNTA always reported negative net income.
CNTA had a negative operating cash flow in each of the past 5 years.
CNTA Yearly Net Income VS EBIT VS OCF VS FCFCNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -46.75%, CNTA is in line with its industry, outperforming 52.10% of the companies in the same industry.
CNTA's Return On Equity of -66.67% is in line compared to the rest of the industry. CNTA outperforms 58.32% of its industry peers.
Industry RankSector Rank
ROA -46.75%
ROE -66.67%
ROIC N/A
ROA(3y)-43.84%
ROA(5y)-56.63%
ROE(3y)-62.33%
ROE(5y)-121.68%
ROIC(3y)N/A
ROIC(5y)N/A
CNTA Yearly ROA, ROE, ROICCNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTA Yearly Profit, Operating, Gross MarginsCNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CNTA has more shares outstanding
CNTA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CNTA has been reduced compared to a year ago.
CNTA Yearly Shares OutstandingCNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CNTA Yearly Total Debt VS Total AssetsCNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CNTA has an Altman-Z score of 5.58. This indicates that CNTA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.58, CNTA is in the better half of the industry, outperforming 78.06% of the companies in the same industry.
A Debt/Equity ratio of 0.32 indicates that CNTA is not too dependend on debt financing.
CNTA has a Debt to Equity ratio of 0.32. This is in the lower half of the industry: CNTA underperforms 70.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 5.58
ROIC/WACCN/A
WACC9.28%
CNTA Yearly LT Debt VS Equity VS FCFCNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 10.00 indicates that CNTA has no problem at all paying its short term obligations.
CNTA has a better Current ratio (10.00) than 81.17% of its industry peers.
CNTA has a Quick Ratio of 10.00. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CNTA (10.00) is better than 81.17% of its industry peers.
Industry RankSector Rank
Current Ratio 10
Quick Ratio 10
CNTA Yearly Current Assets VS Current LiabilitesCNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

CNTA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.92%.
The Revenue has grown by 118.88% in the past year. This is a very strong growth!
EPS 1Y (TTM)1.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
Revenue 1Y (TTM)118.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.21% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.5%
EPS Next 2Y1.38%
EPS Next 3Y-1.22%
EPS Next 5Y20.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTA Yearly Revenue VS EstimatesCNTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2028 2029 2030 2031 2032 500M 1B 1.5B
CNTA Yearly EPS VS EstimatesCNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTA Price Earnings VS Forward Price EarningsCNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTA Per share dataCNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.38%
EPS Next 3Y-1.22%

More info and screens

0

5. Dividend

5.1 Amount

CNTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (8/25/2025, 8:12:08 PM)

After market: 17 0 (0%)

17

-0.01 (-0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners83.92%
Inst Owner Change-5.15%
Ins Owners0.49%
Ins Owner Change-1.09%
Market Cap2.28B
Analysts85.26
Price Target32.54 (91.41%)
Short Float %3.6%
Short Ratio3.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.69%
Min EPS beat(2)-7.99%
Max EPS beat(2)47.36%
EPS beat(4)2
Avg EPS beat(4)6.17%
Min EPS beat(4)-27.41%
Max EPS beat(4)47.36%
EPS beat(8)5
Avg EPS beat(8)10.21%
EPS beat(12)8
Avg EPS beat(12)9.45%
EPS beat(16)10
Avg EPS beat(16)7.42%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.47%
EPS NQ rev (1m)-7.91%
EPS NQ rev (3m)12.18%
EPS NY rev (1m)-6.16%
EPS NY rev (3m)5.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)10%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 151.95
P/FCF N/A
P/OCF N/A
P/B 6.61
P/tB 6.61
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.11
BVpS2.57
TBVpS2.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.75%
ROE -66.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.84%
ROA(5y)-56.63%
ROE(3y)-62.33%
ROE(5y)-121.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.78%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10
Quick Ratio 10
Altman-Z 5.58
F-Score3
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)300.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
EPS Next Y18.5%
EPS Next 2Y1.38%
EPS Next 3Y-1.22%
EPS Next 5Y20.21%
Revenue 1Y (TTM)118.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.4%
EBIT Next 3Y-16.33%
EBIT Next 5YN/A
FCF growth 1Y21.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.12%
OCF growth 3YN/A
OCF growth 5YN/A